Immune pathway upregulation and lower genomic instability distinguish EBV-positive nodal T/NK-cell lymphoma from ENKTL and PTCL-NOS
Cho Mar Myint Wai, Shangying Chen, The Phyu, Shuangyi Fan, Sai Mun Leong, Wenning Zheng, Louis Ching Yi Low, Shoa‐Nian Choo, Chi-Kuen Lee, Tae‐Hoon Chung, Kenneth Ban, Soumita Ghosh, Stefanus Lie, Seiichi Kato, Shigeo Nakamura, Emiko Takahashi, Young Hyeh Ko, Joseph D. Khoury, Shih‐Sung Chuang, Rex Au-Yeung, Soo‐Yong Tan, Soon-Thye Lim, Choon Kiat Ong, Yong-Howe Ho, Li Mei Poon, Sanjay De Mel, Anand D. Jeyasekharan, Wee Joo Chng, Franziska Otto, Leticia Quintanilla‐Martínez, Federica Zanardi, Fabio Iannelli, Claudio Tripodo, Jason J. Pitt, Siok‐Bian Ng
Abstract
Primary Epstein-Barr virus (EBV)-positive nodal T/NK-cell lymphoma (PTCL-EBV) is a poorly understood disease which shows features resembling extranodal NK/T-cell lymphoma (ENKTL) and is currently not recognized as a distinct entity but categorized as a variant of primary T-cell lymphoma not otherwise specified (PTCL-NOS). Herein, we analyzed copynumber aberrations (n=77) with a focus on global measures of genomic instability and homologous recombination deficiency and performed gene expression (n=84) and EBV miRNA expression (n=24) profiling as well as targeted mutational analysis (n=16) to further characterize PTCL-EBV in relation to ENKTL and PTCL-NOS. Multivariate analysis revealed that patients with PTCL-EBV had a significantly worse outcome compared to patients with PTCL-NOS (P=0.002) but not to those with ENKTL. Remarkably, PTCL-EBV exhibited significantly lower genomic instability and homologous recombination deficiency scores compared to ENKTL and PTCL-NOS. Gene set enrichment analysis revealed that many immune-related pathways, interferon α/γ response, and IL6_JAK_STAT3 signaling were significantly upregulated in PTCLEBV and correlated with lower genomic instability scores. We also identified that NFκB-associated genes, BIRC3, NFKB1 (P50) and CD27, and their proteins are upregulated in PTCL-EBV. Most PTCL-EBV demonstrated a type 2 EBV latency pattern and, strikingly, exhibited downregulated expression of most EBV miRNA compared to ENKTL and their target genes were also enriched in immune-related pathways. PTCL-EBV also showed frequent mutations of TET2, PIK3CD and STAT3, and are characterized by microsatellite stability. Overall, poor outcome, low genomic instability, upregulation of immune pathways and downregulation of EBV miRNA are distinctive features of PTCL-EBV. Our data support the concept that PTCL-EBV could be considered as a distinct entity, provide novel insights into the pathogenesis of the disease and offer potential new therapeutic targets for this tumor.